Literature DB >> 9131273

Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression.

S Y Rha1, J H Kim, J K Roh, K S Lee, J S Min, B S Kim, H C Chung.   

Abstract

The degradation of the basement membrane by matrix-metalloproteinase (MMP) and serine protease is a critical point in tumor invasion and metastasis. We measured the activity of MMP-9 from 28 normal, 12 benign and 126 breast cancer tissues using gelatin zymography with an image analysis system. ProMMP-9 was expressed in 17.5% of the cancer patients compared to 2.5% in 40 non-cancerous tissues (p = 0.014). The mature form of MMP-9 (82 kD) was expressed only in T2-T4 stages. During the early phase of breast cancer (DCIS and T1 stage) progression, only production of proMMP-9 increased. However, as the cancer grew or invaded skin (T2-T4), or with lymphovascular permeation, both production and activation of MMP-9 increased. In conclusion, proMMP-9 production was the main cause of increased MMP-9 activity during the early phase, while both production and activation increased in the late phase of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9131273     DOI: 10.1023/a:1005701231871

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  14 in total

1.  MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits.

Authors:  A M Tester; N Ruangpanit; R L Anderson; E W Thompson
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression.

Authors:  M E Kupferman; M E Fini; W J Muller; R Weber; Y Cheng; R J Muschel
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer.

Authors:  J Kleeff; H Friess; P Simon; S Susmallian; P Büchler; A Zimmermann; M W Büchler; M Korc
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

4.  Tumor necrosis factor-alpha-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase.

Authors:  Yuan-Ping Han; Yih-Dar Nien; Warren L Garner
Journal:  J Biol Chem       Date:  2002-05-09       Impact factor: 5.157

5.  Tumour-stromal interactions in acid-mediated invasion: a mathematical model.

Authors:  Natasha K Martin; Eamonn A Gaffney; Robert A Gatenby; Philip K Maini
Journal:  J Theor Biol       Date:  2010-09-08       Impact factor: 2.691

6.  Transforming growth factor-beta - and tumor necrosis factor-alpha -mediated induction and proteolytic activation of MMP-9 in human skin.

Authors:  Y P Han; T L Tuan; M Hughes; H Wu; W L Garner
Journal:  J Biol Chem       Date:  2001-04-10       Impact factor: 5.157

7.  Co-stimulation of human breast cancer cells with transforming growth factor-beta and tenascin-C enhances matrix metalloproteinase-9 expression and cancer cell invasion.

Authors:  Kalembeyi Ilunga; Rika Nishiura; Hiroyasu Inada; Amro El-Karef; Kyoko Imanaka-Yoshida; Teruyo Sakakura; Toshimichi Yoshida
Journal:  Int J Exp Pathol       Date:  2004-12       Impact factor: 1.925

8.  Proteolytic activation of matrix metalloproteinase-9 in skin wound healing is inhibited by alpha-1-antichymotrypsin.

Authors:  Yuan-Ping Han; Chunli Yan; Warren L Garner
Journal:  J Invest Dermatol       Date:  2008-04-10       Impact factor: 8.551

9.  Leptin utilizes Jun N-terminal kinases to stimulate the invasion of MCF-7 breast cancer cells.

Authors:  Vanity McMurtry; Ann-Marie Simeone; René Nieves-Alicea; Ana M Tari
Journal:  Clin Exp Metastasis       Date:  2008-12-27       Impact factor: 5.150

10.  Cooperation between monocytes and breast cancer cells promotes factors involved in cancer aggressiveness.

Authors:  E Blot; W Chen; M Vasse; J Paysant; C Denoyelle; J-Y Pillé; L Vincent; J-P Vannier; J Soria; C Soria
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.